Literature DB >> 12069959

Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.

Hugues Loemba1, Bluma Brenner, Michael A Parniak, Shlomo Ma'ayan, Bonnie Spira, Daniela Moisi, Maureen Oliveira, Mervi Detorio, Mark A Wainberg.   

Abstract

We sequenced and phylogenetically analyzed the reverse transcriptase (RT) region of five human immunodeficiency virus type 1 isolates from treatment-naive Ethiopian émigrés to Israel. Heteroduplex mobility assays were performed to confirm the clade C status of env genomic regions. The RT sequences showed that the strains clustered phylogenetically with clade C viruses, and a KVEQ-specific motif of silent mutations (amino acids 65, 106, 138, and 161, respectively) at resistance sites was present in the polymerase region of all studied Ethiopian isolates and subtype C reference strains. In addition, many other silent mutations were observed in the clade C viruses at various resistance sites. In general, the Ethiopian isolates were more closely related genotypically to a clade C reference strain from Botswana (southern Africa) than to previously sequenced Ethiopian reference strains. Genotypic analysis showed that two Ethiopian isolates naturally harbored the mutations K70R and G190A associated with resistance to ZDV and nonnucleoside reverse transcriptase inhibitors, respectively. Phenotypic assays revealed that the K70R substitution in this context did not reduce susceptibility to ZDV, whereas the G190A substitution resulted in high-level resistance to nevirapine (NVP). Moreover, variants resistant to NVP, delavirdine (DLV), and efavirenz (EFV) were more rapidly selected at lower drug doses culture with clade C than with clade B wild-type isolates. In the case of subtype C, selection with NVP and/or EFV led to the appearance of several previously unseen mutations in RT, i.e., V106M and S98I, as well as other mutations that have been previously reported (e.g., K103N, V106A, V108I, and Y181C). After selection with DLV, a polymorphism, A62A, initially observed in the Ethiopian isolate 4762, mutated to A62V; the latter is a secondary substitution associated with multidrug resistance against nucleoside RT inhibitors. Phenotypic analysis of clade C mutants selected against NVP, DLV, and EFV revealed broad cross-resistance, particularly in regard to NVP and DLV. These findings suggest that RT genotypic diversity may influence the emergence of drug resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12069959      PMCID: PMC127309          DOI: 10.1128/AAC.46.7.2087-2094.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B.

Authors:  Z Grossman; N Vardinon; D Chemtob; M L Alkan; Z Bentwich; M Burke; G Gottesman; V Istomin; I Levi; S Maayan; E Shahar; J M Schapiro
Journal:  AIDS       Date:  2001-08-17       Impact factor: 4.177

2.  The impact of HIV-1 subtype on drug resistance.

Authors:  D Mital; D Pillay
Journal:  J HIV Ther       Date:  2001-08

3.  R211K and L214F do not invariably confer high level phenotypic resistance to thymidine analogs in zidovudine-naive patients with M184V.

Authors:  C Torti; Y Gilleece; K Hertogs; B G Gazzard; A L Pozniak
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-15       Impact factor: 3.731

4.  HIV-1 in Ethiopia: phylogenetic divergence from other HIV-1 strains.

Authors:  S Ayehunie; B Johansson; M Salminen; P Leinikki; A Sönnerborg; D W Zewdie; S Britton; O Strannegård
Journal:  Virus Genes       Date:  1991-10       Impact factor: 2.332

5.  In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.

Authors:  Q Gao; Z X Gu; M A Parniak; X G Li; M A Wainberg
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

6.  Serological survey of human immunodeficiency virus (HIV) in Ethiopia.

Authors:  K Hailù; S Buttò; D Bekura; P Verani; F Titti; L Sernicola; M Rapicetta; P Pasquini; G B Rossi
Journal:  J Med Virol       Date:  1989-05       Impact factor: 2.327

7.  Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.

Authors:  J B Jackson; G Becker-Pergola; L A Guay; P Musoke; M Mracna; M G Fowler; L M Mofenson; M Mirochnick; F Mmiro; S H Eshleman
Journal:  AIDS       Date:  2000-07-28       Impact factor: 4.177

8.  Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients.

Authors:  A J Frater; A Beardall; K Ariyoshi; D Churchill; S Galpin; J R Clarke; J N Weber; M O McClure
Journal:  AIDS       Date:  2001-08-17       Impact factor: 4.177

9.  Timing of the HIV-1 subtype C epidemic in Ethiopia based on early virus strains and subsequent virus diversification.

Authors:  A Abebe; V V Lukashov; G Pollakis; A Kliphuis; A L Fontanet; J Goudsmit; T F de Wit
Journal:  AIDS       Date:  2001-08-17       Impact factor: 4.177

10.  Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.

Authors:  L Bacheler; S Jeffrey; G Hanna; R D'Aquila; L Wallace; K Logue; B Cordova; K Hertogs; B Larder; R Buckery; D Baker; K Gallagher; H Scarnati; R Tritch; C Rizzo
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

View more
  44 in total

1.  Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies.

Authors:  M Gordon; T De Oliveira; K Bishop; H M Coovadia; L Madurai; S Engelbrecht; E Janse van Rensburg; A Mosam; A Smith; S Cassol
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

2.  Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.

Authors:  Michel Ntemgwa; Bluma G Brenner; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.

Authors:  Florence Doualla-Bell; Ava Avalos; Tendani Gaolathe; Madisa Mine; Simani Gaseitsiwe; Ndwapi Ndwapi; Vladimir A Novitsky; Bluma Brenner; Maureen Oliveira; Daniella Moisi; Howard Moffat; Ibou Thior; Max Essex; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 4.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

5.  Drug resistance mutation profile and accumulation kinetics in human immunodeficiency virus-positive individuals infected with subtypes B and F failing highly active antiretroviral therapy are influenced by different viral codon usage patterns.

Authors:  A Waléria-Aleixo; A N Martins; M B Arruda; R M Brindeiro; R M Da-Silva; F F Nobre; D B Greco; A Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

6.  Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options.

Authors:  Ashika Singh; Henry Sunpath; Taryn N Green; Nagavelli Padayachi; Keshni Hiramen; Yolanda Lie; Elizabeth D Anton; Richard Murphy; Jacqueline D Reeves; Daniel R Kuritzkes; Thumbi Ndung'u
Journal:  J Acquir Immune Defic Syndr       Date:  2011-11-01       Impact factor: 3.731

7.  Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.

Authors:  Karidia Diallo; Du-Ping Zheng; Erin K Rottinghaus; Orji Bassey; Chunfu Yang
Journal:  AIDS Res Hum Retroviruses       Date:  2015-02-05       Impact factor: 2.205

8.  Subtype-associated differences in HIV-1 reverse transcription affect the viral replication.

Authors:  Sergey Iordanskiy; Mackenzie Waltke; Yanjun Feng; Charles Wood
Journal:  Retrovirology       Date:  2010-10-12       Impact factor: 4.602

9.  Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1.

Authors:  Dan Turner; Bluma Brenner; Daniela Moisi; Mervi Detorio; Raymond Cesaire; Takashi Kurimura; Haruyo Mori; Max Essex; Shlomo Maayan; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 10.  Efavirenz--still first-line king?

Authors:  Brookie M Best; Miguel Goicoechea
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-07       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.